Literature DB >> 3022849

Cell kinetics of histologic variants of in situ breast carcinoma.

J S Meyer.   

Abstract

A thymidine labeling study of cell kinetics of 61 in situ breast carcinomas showed relationships between histological characteristics and kinetics. The thymidine labeling index (TLI) was significantly lower in cribriform-papillary intraductal carcinoma (median 1.30%, geometric mean 1.18%, mean 1.83 +/- 0.45%) and lobular carcinoma in situ (median 1.43%, geometric mean 1.12%, mean 1.63 +/- 0.46%) than in comedo intraductal carcinoma (median 4.40%, geometric mean 3.74%, mean 5.15 +/- 0.86%). The results for solid intraductal carcinoma, which is a less well defined and more heterogeneous entity, were intermediate (median 2.45%, geometric mean 2.40%, mean 3.32 +/- 0.80%). When invasive carcinoma was also available for kinetic study, the TLI of in situ and invasive components were usually similar (r = 0.66). The data indicate that the TLI usually does not change during the transition from in situ to invasive carcinoma. Cribriform-papillary intraductal carcinoma is a slowly proliferating entity that gives rise to slowly proliferating invasive carcinomas with relatively high levels of estrogen and progesterone receptors. Lobular carcinoma in situ similarly has low proliferative rates and gives rise to slowly proliferating invasive carcinomas. Intraductal comedocarcinoma has relatively high proliferative rates and gives rise to invasive carcinomas with high proliferative rates that often are receptor-negative. Nine of the 11 in situ carcinomas that were associated with invasive tumor and subsequent local recurrence or metastasis had TLIs above the median, and seven were comedo type with high TLIs. Our observations from thymidine labeling are consistent with a viewpoint regarding cribriform-papillary intraductal carcinoma as relatively bland, and comedo intraductal carcinoma as a distinctly more dangerous entity. Solid intraductal carcinoma seems to resemble cribriform-papillary more closely than comedo intraductal carcinoma.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3022849     DOI: 10.1007/bf01806247

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  34 in total

1.  The pathology of invasive breast cancer. A syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol no. 4).

Authors:  E R Fisher; R M Gregorio; B Fisher; C Redmond; F Vellios; S C Sommers
Journal:  Cancer       Date:  1975-07       Impact factor: 6.860

2.  Estrogen receptor heterogeneity and the relationship between estrogen receptor and the tritiated thymidine labeling index in human breast cancer.

Authors:  M J Straus; R Moran; R E Muller; H H Wotiz
Journal:  Oncology       Date:  1982       Impact factor: 2.935

3.  In vitro labeling of solid tissues with tritiated thymidine for autoradiographic detection of S-phase nuclei.

Authors:  J S Meyer; R E Connor
Journal:  Stain Technol       Date:  1977-07

4.  Heterogeneity of breast carcinomas determined by flow cytometric analysis.

Authors:  M U Prey; J S Meyer; K R Stone; R W McDivitt
Journal:  J Surg Oncol       Date:  1985-05       Impact factor: 3.454

5.  Intraductal carcinoma of the breast: follow-up after biopsy only.

Authors:  D L Page; W D Dupont; L W Rogers; M Landenberger
Journal:  Cancer       Date:  1982-02-15       Impact factor: 6.860

6.  Prediction of early course of breast carcinoma by thymidine labeling.

Authors:  J S Meyer; E Friedman; M M McCrate; W C Bauer
Journal:  Cancer       Date:  1983-05-15       Impact factor: 6.860

7.  Advanced stage and early relapse of breast carcinomas associated with high thymidine labeling indices.

Authors:  J S Meyer; B Hixon
Journal:  Cancer Res       Date:  1979-10       Impact factor: 12.701

8.  Cell kinetics as a prognostic marker in node-negative breast cancer.

Authors:  R Silvestrini; M G Daidone; G Gasparini
Journal:  Cancer       Date:  1985-10-15       Impact factor: 6.860

9.  Estrogen receptor assay of carcinomas of the breast by a simplified dextran--charcoal method.

Authors:  J S Meyer; S C Stevens; W L White; B Hixon
Journal:  Am J Clin Pathol       Date:  1978-10       Impact factor: 2.493

10.  Relationship of steroid receptor, cell kinetics, and clinical status in patients with breast cancer.

Authors:  T E Kute; H B Muss; D Anderson; K Crumb; B Miller; D Burns; L A Dube
Journal:  Cancer Res       Date:  1981-09       Impact factor: 12.701

View more
  25 in total

1.  Biological grading of breast cancer using antibodies to proliferating cells and other markers.

Authors:  S S Bacus; R Goldschmidt; D Chin; G Moran; D Weinberg; J W Bacus
Journal:  Am J Pathol       Date:  1989-11       Impact factor: 4.307

2.  Relationship between c-erbB-2 immunoreactivity and thymidine labelling index in breast carcinoma in situ.

Authors:  D M Barnes; J S Meyer; J G Gonzalez; W J Gullick; R R Millis
Journal:  Breast Cancer Res Treat       Date:  1991-03       Impact factor: 4.872

Review 3.  Management of ductal carcinoma in situ of the breast.

Authors:  N J Carty; C Carter; G T Royle; C D Johnson
Journal:  Ann R Coll Surg Engl       Date:  1995-05       Impact factor: 1.891

4.  Differential distribution of ErbB-2 and pS2 proteins in ductal carcinoma in situ of the breast.

Authors:  H Inaji; H Koyama; K Motomura; S Noguchi
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

5.  Nuclear and flow cytometric characteristics associated with overexpression of the c-erbB-2 oncoprotein in breast carcinoma.

Authors:  D N Poller; M Galea; D Pearson; J Bell; W J Gullick; C W Elston; R W Blamey; I O Ellis
Journal:  Breast Cancer Res Treat       Date:  1991-12       Impact factor: 4.872

6.  Alterations in galectin-3 expression and distribution correlate with breast cancer progression: functional analysis of galectin-3 in breast epithelial-endothelial interactions.

Authors:  Malathy P V Shekhar; Pratima Nangia-Makker; Larry Tait; Fred Miller; Avraham Raz
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

7.  Ki-67 staining in histological subtypes of breast carcinoma and fine needle aspiration smears.

Authors:  V Kuenen-Boumeester; T H Van Der Kwast; H A Van Laarhoven; S C Henzen-Logmans
Journal:  J Clin Pathol       Date:  1991-03       Impact factor: 3.411

Review 8.  Management of in situ and minimally invasive breast carcinoma.

Authors:  E R Frykberg; K I Bland
Journal:  World J Surg       Date:  1994 Jan-Feb       Impact factor: 3.352

Review 9.  Biological features of premalignant disease in the human breast.

Authors:  D C Allred; S K Mohsin
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-10       Impact factor: 2.673

10.  Comedo-ductal carcinoma in situ: A paradoxical role for programmed cell death.

Authors:  Malathy P V Shekhar; Larry Tait; Robert J Pauley; Gen Sheng Wu; Steven J Santner; Pratima Nangia-Makker; Varun Shekhar; Hind Nassar; Daniel W Visscher; Gloria H Heppner; Fred R Miller
Journal:  Cancer Biol Ther       Date:  2008-11-12       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.